Cargando…

Sex work involvement among women with long-term opioid injection drug dependence who enter opioid agonist treatment

BACKGROUND: Substitution with opioid-agonists (e.g., methadone) has shown to be an effective treatment for chronic long-term opioid dependency. Survival sex work, very common among injection drug users, has been associated with poor Opioid Agonist Treatment (OAT) engagement, retention and response....

Descripción completa

Detalles Bibliográficos
Autores principales:	Marchand, Kirsten, Oviedo-Joekes, Eugenia, Guh, Daphne, Marsh, David C, Brissette, Suzanne, Schechter, Martin T
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3281790/ https://www.ncbi.nlm.nih.gov/pubmed/22276954 http://dx.doi.org/10.1186/1477-7517-9-8

Ejemplares similares

Client satisfaction among participants in a randomized trial comparing oral methadone and injectable diacetylmorphine for long-term opioid-dependency
por: Marchand, Kirsten I, et al.
Publicado: (2011)

Differential long-term outcomes for voluntary and involuntary transition from injection to oral opioid maintenance treatment
por: Oviedo-Joekes, Eugenia, et al.
Publicado: (2014)

Men’s and women’s response to treatment and perceptions of outcomes in a randomized controlled trial of injectable opioid assisted treatment for severe opioid use disorder
por: Palis, Heather, et al.
Publicado: (2017)

Adverse Events During Treatment Induction With Injectable Diacetylmorphine and Hydromorphone for Opioid Use Disorder
por: Oviedo-Joekes, Eugenia, et al.
Publicado: (2019)

The SALOME study: recruitment experiences in a clinical trial offering injectable diacetylmorphine and hydromorphone for opioid dependency
por: Oviedo-Joekes, Eugenia, et al.
Publicado: (2015)

The Impact of Injectable Opioid Agonist Treatment (iOAT) on Involvement in Criminalized Activities: A Secondary Analysis from a Clinical Trial in Vancouver, BC
por: Dobischok, Sophia, et al.
Publicado: (2023)

The association between nicotine dependence and physical health among people receiving injectable diacetylmorphine or hydromorphone for the treatment of chronic opioid use disorder()
por: Palis, Heather, et al.
Publicado: (2018)

Building healthcare provider relationships for patient-centered care: A qualitative study of the experiences of people receiving injectable opioid agonist treatment
por: Marchand, Kirsten, et al.
Publicado: (2020)

Exploring the effectiveness of dextroamphetamine for the treatment of stimulant use disorder: a qualitative study with patients receiving injectable opioid agonist treatment
por: Palis, Heather, et al.
Publicado: (2021)

Changes in daily dose in open-label compared to double-blind: The role of clients’ expectations in injectable opioid agonist treatment
por: Blawatt, Sarin, et al.
Publicado: (2023)

Feasibility of Testing Client Preferences for Accessing Injectable Opioid Agonist Treatment (iOAT): A Pilot Study
por: Dobischok, Sophia, et al.
Publicado: (2022)

The Role of Gender in Factors Associated With Addiction Treatment Satisfaction Among Long-Term Opioid Users
por: Marchand, Kirsten, et al.
Publicado: (2015)

A chance to stop and breathe: participants’ experiences in the North American Opiate Medication Initiative clinical trial
por: Oviedo-Joekes, Eugenia, et al.
Publicado: (2014)

Use of sustained release dextroamphetamine for the treatment of stimulant use disorder in the setting of injectable opioid agonist treatment in Canada: a case report
por: Palis, Heather, et al.
Publicado: (2021)

Take home injectable opioids for opioid use disorder during and after the COVID-19 Pandemic is in urgent need: a case study
por: Oviedo-Joekes, Eugenia, et al.
Publicado: (2021)

Feasibility of Applying the Life History Calendar in a Population of Chronic Opioid Users to Identify Patterns of Drug Use and Addiction Treatment
por: Fikowski, Jill, et al.
Publicado: (2014)

“As long as that place stays open, I’ll stay alive”: Accessing injectable opioid agonist treatment during dual public health crises
por: Jaffe, Kaitlyn, et al.
Publicado: (2023)

Clients’ experiences on North America’s first take-home injectable opioid agonist treatment (iOAT) program: a qualitative study
por: Oviedo-Joekes, Eugenia, et al.
Publicado: (2023)

The impact of relaxing restrictions on take-home doses during the COVID-19 pandemic on program effectiveness and client experiences in opioid agonist treatment: a mixed methods systematic review
por: Adams, Alison, et al.
Publicado: (2023)

Evidence of Increased Age and Sex Standardized Death Rates Among Individuals Who Accessed Opioid Agonist Treatment Before the Era of Synthetic Opioids in Ontario, Canada
por: Morin, Kristen A, et al.
Publicado: (2021)

A critical analysis of user satisfaction surveys in addiction services: opioid maintenance treatment as a representative case study
por: Trujols, Joan, et al.
Publicado: (2014)

Provider experiences with relaxing restrictions on take-home medications for opioid use disorder during the COVID-19 pandemic: A qualitative systematic review
por: Adams, Alison, et al.
Publicado: (2023)

Patient-centred care for addiction treatment: a scoping review protocol
por: Marchand, Kirsten, et al.
Publicado: (2018)

Conceptualizing patient-centered care for substance use disorder treatment: findings from a systematic scoping review
por: Marchand, Kirsten, et al.
Publicado: (2019)

Sustained Virologic Response in People Who Inject Drugs and/or Who Are on Opioid Agonist Therapy: Is 90% Enough?
por: Naggie, Susanna, et al.
Publicado: (2019)

Importance of Opioid Agonist Therapy to Reduce Injection-Related Infections
por: Weaver, Victoria K, et al.
Publicado: (2022)

Breastfeeding on Injectable Opioid Agonist Therapy: A Case Report
por: Patricelli, Charissa J., et al.
Publicado: (2023)

Effectiveness of Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in People Who Inject Drugs and/or Those in Opioid Agonist Therapy
por: Janjua, Naveed Z., et al.
Publicado: (2019)

Psychopathological symptoms of patients with heroin addiction entering opioid agonist or therapeutic community treatment
por: Pani, Pier Paolo, et al.
Publicado: (2014)

Perceptions of extended‐release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia
por: Larance, Briony, et al.
Publicado: (2020)

Better agonist for the opioid receptors
por: Badshah, Syed Lal, et al.
Publicado: (2018)

HCV/HIV coinfection among people who inject drugs and enter opioid substitution treatment in Greece: prevalence and correlates
por: Fotiou, Anastasios, et al.
Publicado: (2016)

Interim opioid agonist treatment for opioid addiction: a systematic review
por: Samsó Jofra, Laura, et al.
Publicado: (2022)

Molecular Physiology of Enteric Opioid Receptors
por: Galligan, James J., et al.
Publicado: (2014)

NAOMI: The trials and tribulations of implementing a heroin assisted treatment study in North America
por: Gartry, Candice C, et al.
Publicado: (2009)

Novel Synthetic Opioids (NSO) Use in Opioid Dependents Entering Detoxification Treatment
por: Specka, Michael, et al.
Publicado: (2022)

People who inject oral morphine favor experimentation with injectable opioid substitution
por: Bertin, Célian, et al.
Publicado: (2023)

Differences in receipt of opioid agonist treatment and time to enter treatment for opioid use disorder among specialty addiction programs in the United States, 2014-17
por: Yang, Justin C., et al.
Publicado: (2019)

The effect of opioid analgesics, benzodiazepines, gabapentinoids, and opioid agonist treatment on mortality risk among opioid-dependent people.
por: Bharat, Chrianna, et al.
Publicado: (2022)

Alcohol use in opioid agonist treatment
por: Nolan, Seonaid, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_s6e2rrjn5ag0e4aokk8og5tn1s